Joint Formulary & PAD

Sulthiame - Epilepsy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Oral suspension
Associated Icons :
BNF SPC
NFD2
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Sulthiame
Indication :
Epilepsy
Group Name :
Keywords :
Rolandic epilepsy
Brand Names Include :
Ospolot
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Sulthiame is used to treat.

  • No records returned.

Committee Recommendations (1)

05 Mar 25 - Not Set

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.